Find Nonprofit and Small Business Grants

Advance Search

Only Available for Paid Subscribers
Clear Filters
Search Filters

Grants to USA, Canada, and International Nonprofits, Institutions, and Researchers for Cancer Research Projects

RUNX1 Research Program (RRP): Research Accelerating RUNX1 Exploration (RARE) Grant


GrantWatch ID#

Funding Source
Array ( [0] => American Samoa (USA); [1] => Guam (USA); [2] => Puerto Rico (USA); [3] => Virgin Islands (USA); [4] => Northern Mariana Islands (USA); )

Geographic Focus
USA Territories: American Samoa (USA);   Guam (USA);   Puerto Rico (USA);   Virgin Islands (USA);   Northern Mariana Islands (USA);
USA Compact Free Associations:The Federated States of Micronesia (USA)   Marshall Islands (USA)   Republic of Palau (USA)
International, Israel and Canada.

Important Dates
Deadline: 12/04/23 8:00 PM ET Save

Grant Description
Grants to USA, Canada, and International nonprofit institutions, organizations, and researchers for cancer research projects. Funding is intended to support research into drug therapies that can slow down or prevent the development of a precancer state to cancer in patients with RUNX1-FPD.

The Research Accelerating RUNX1 Exploration Grant is designed to fund research that will lead to the development of therapies for patients with RUNX1-FPD that will either intercept the transition from a precancer state (clonal hematopoiesis) to MDS/AML or prevention of cancer (before clonal hematopoiesis). 

Aims of research proposals must be relevant to the goal of preventing hematologic malignant transformation in RUNX1-FPD. Proposals that seek to translate from bench to bedside will receive priority. 

The following areas of research are of priority and are not ranked according to their order:

  • Drug Repurposing and Clinical Translation
    • Support for preclinical experiments and correlative clinical studies designed to test regulatory-approved agents for the rescue of RUNX1-FPD hematopoietic function and interception of high-risk clonal hematopoiesis.
  • RUNX1 Biology
    • Characterize the normal function of RUNX1 and the function of germline RUNX1 mutant proteins. High interest in defining the role of RUNX1 in DNA damage repair in HSCs and the potential role germline RUNX1 mutations may play in acquisition of somatic mutations.
    • Identify regulators of RUNX1 expression and function to discover novel methods of correcting RUNX1 function within the hematopoietic system.
  • Discovery
    • Investigate feasibility of targeting RNA splicing for disease therapy in patients with splicesite mutations or nonsense suppression therapies for patients with nonsense mutations.
    • Develop therapeutic strategies to raise normal RUNX1 activity or RUNX1 protein levels to improve hematopoietic function and reduce HM risk.
    • Identify druggable mechanisms, with a focus on drug repurposing, that drive clonal hematopoiesis, clonal expansion and ultimately malignant transformation in RUNX1-FPD patients.
      1. Projects should focus on targeting clones with common co-occurring mutations in RUNX1-FPD (i.e. BCOR, TET2, PHF6, SRSF2). 


Additional Eligibility Criteria
- Applicant institutions may be based in the U.S. or outside of the U.S. Applicants need not be United States citizens. Funds must be granted to non-profit institutions or organizations.
- Applicants must have an MD, PhD, or MD/PhD (DO, MBBS or equivalent).
- Applicants may have research grants from other funding sources during the award period, but there must be clear documentation of mechanisms to avoid scientific and budgetary overlap.
- Applicants must have research experience working in, and a deep understanding of, normal or malignant hematopoiesis and/or immunology.

- The RUNX1 Early Career Grant is not transferable to another investigator.
- RRP/ALSF does not fund proposals for research utilizing human embryonic stem cells or non-human primates. Research with human induced pluripotent stem cells is permissible.

Indirect costs are not allowed.

RRP/ALSF funds cannot be used for tuition remission.

Pre-Application Information
- Application Deadline: December 4, 2023, 8 PM (ET)
- Award Notification Date: February, 2024
- Project Start/End Date: April 2024-April 2026


Estimated Size of Grant
A maximum of $125,000 in total costs may be requested per year.

Term of Contract
The Research Accelerating RUNX1 Exploration Grant is a two-year award.

Project Start/End Date: April 2024-April 2026

The grant may not be renewed; one no-cost extension request is allowed.

Contact Information
Apply online:

If you have any questions regarding your eligibility or your research proposal topic, the Foundation encourages you to reach out to Katrin Ericson, Executive Director at RRP at

All other questions can be submitted to Margaret Poore at

Alex’s Lemonade Stand Foundation for Childhood Cancer
333 E. Lancaster Ave, #414
Wynnewood, PA 19096 USA
Phone: 866.333.1213

Grant News
Live Chat Chat Now